IP Library Patent Application 17045411
Patent Application
App. No. 17/045,411

MATERIALS AND METHODS FOR TREATING CANCER

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/045,411
Abstract

This document provides methods for determining biological age of mammalian subjects or assessing whether the subjects are aging normally. Also provided herein are methods for determining whether therapeutic treatment or other interventions for reversing or slowing down aging are effective. This document also provides methods and materials for slowing the progression of biological aging.

Claims (24)

1 . A method for treating cancer, wherein said method comprises administering an AXL inhibitor to a mammal having cancer that received an adoptive T cell therapy to treat said cancer.

2 . The method of claim 1 , wherein said mammal is a human.

3 . The method of claim 1 , wherein said cancer is a lymphoma.

4 . The method of claim 3 , wherein said lymphoma is a diffuse large B cell lymphoma.

5 . The method of claim 1 , wherein said cancer is a leukemia.

6 . The method of claim 5 , wherein said leukemia is an acute lymphoblastic leukemia or a chronic lymphocytic leukemia.

7 . The method of claim 1 , wherein said AXL inhibitor is TP0903.

8 - 20 . (canceled)

21 . A method for treating cancer, wherein said method comprises administering T cells to a mammal having cancer, wherein said T cells were contacted with an AXL inhibitor.

22 . The method of claim 21 , wherein said mammal is a human.

23 . The method of claim 21 , wherein said cancer is a lymphoma.

24 . The method of claim 23 , wherein said lymphoma is a diffuse large B cell lymphoma.

25 . The method of claim 21 , wherein said cancer is a leukemia.

26 . The method of claim 25 , wherein said leukemia is an acute lymphoblastic leukemia or a chronic lymphocytic leukemia.

27 . The method of claim 21 , wherein said AXL inhibitor is TP0903.

28 - 40 . (canceled)

41 . An ex vivo method for expanding T cells for treating cancer, wherein said method comprises contacting T cells with an AXL inhibitor.

42 . (canceled)

43 . The method of claim 41 , wherein said cancer is a lymphoma.

44 . The method of claim 43 , wherein said lymphoma is a diffuse large B cell lymphoma.

45 . The method of claim 41 , wherein said cancer is a leukemia.

46 . The method of claim 45 , wherein said leukemia is an acute lymphoblastic leukemia or a chronic lymphocytic leukemia.

47 . The method of claim 41 , wherein said AXL inhibitor is TP0903.

48 - 56 . (canceled)

Assignments (5)
CHANGE OF NAME Recorded Apr 27, 2022
From: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
To: SUMITOMO PHARMA ONCOLOGY, INC.
Reel/Frame 059809/0557 →
MERGER Recorded Feb 25, 2021
From: TOLERO PHARMACEUTICALS, INC.
To: BOSTON BIOMEDICAL, INC.
Reel/Frame 055411/0556 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2021
From: WARNER, STEVEN L.; BEARSS, DAVID J.; FOULKS, JASON MARC; MOURITSEN, LARS; WHATCOTT, CLIFFORD J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 055411/0584 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2021
From: KENDERIAN, SAAD J.; KAY, NEIL E.; SAKEMURA, REONA
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 055411/0614 →
CHANGE OF NAME Recorded Feb 25, 2021
From: BOSTON BIOMEDICAL, INC.
To: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
Reel/Frame 055412/0086 →